NEW YORK (360Dx) – Cell-based diagnostics firm Celcuity reported after the close of the market on Thursday that its fourth quarter net losses widened year over year.

For the three months ended Dec. 31, 2017 Celcuity posted a net loss of $1.7 million, or $.17 per share, compared to a net loss of $902,434, or $.14 per share, in the year-ago period. The firm's adjusted loss per share for Q4 2017 was $.14.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.


In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  


This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.


This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.